Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2009 Oct 16;121(2):445–452. doi: 10.1007/s10549-009-0579-7

Table 2.

E-cadherin SNPs and breast cancer risk among all women, premenopausal women, and postmenopausal women, the Shanghai Breast Cancer Study

SNP Allelesa Region Genotypingb MAFc HWEd All women
 Premenopausal womenf
 Postmenopausal womeng
B OR (95% CI)e P valuee B OR (95% CI)e P valuee B OR (95% CI)e P value
rs9989407 T/C Promoter Affy 6.0 25.8 0.560 1.1 (1.0–1.2) 0.334 1.0 (0.9–1.1) 0.673 1.2 (1.0–1.4) 0.045
rs9940250 T/C Promoter Targeted 27.9 0.905 1.0 (0.8–1.1) 0.594 0.9 (0.8–1.1) 0.427 1.0 (0.8–1.3) 0.849
rs7196495 T/C Intron 2 Affy 6.0 25.9 0.630 1.0 (0.9–1.1) 0.409 1.0 (0.9–1.1) 0.635 1.2 (1.0–1.3) 0.065
rs7196661 T/C Intron 2 Affy 6.0 25.9 0.630 1.0 (0.9–1.1) 0.416 1.0 (0.9–1.1) 0.637 1.2 (1.0–1.3) 0.069
rs11865026 T/C Intron 2 Affy 6.0 24.2 0.976 1.0 (0.9–1.1) 0.671 1.0 (0.9–1.2) 0.627 0.9 (0.8–1.1) 0.216
rs7203337 G/C Intron 2 Affy 6.0 49.8 0.630 1.0 (0.9–1.1) 0.724 1.0 (0.9–1.1) 0.999 1.0 (0.8–1.1) 0.569
rs1078621 C/T Intron 2 Affy 6.0 49.2 0.155 1.0 (0.9–1.1) 0.449 1.0 (0.9–1.1) 0.923 0.9 (0.8–1.0) 0.177
rs11642413 G/A Intron 2 Targeted 48.4 0.803 1.0 (0.9–1.2) 0.658 1.0 (0.9–1.2) 0.697 1.0 (0.8–1.3) 0.856
rs9941051 T/C Intron 2 Affy 6.0 25.7 0.423 1.0 (0.9–1.1) 0.428 1.0 (0.9–1.1) 0.712 1.1 (1.0–1.3) 0.097
rs8056538 G/A Intron 2 Affy 6.0 24.1 0.804 1.0 (0.9–1.1) 0.949 1.1 (0.9–1.2) 0.417 0.9 (0.8–1.1) 0.280
rs12444784 A/G Intron 2 Both 8.2 0.069 0.9 (0.8–1.1) 0.352 0.8 (0.7–1.0) 0.058 1.1 (0.9–1.5) 0.342
rs12930371 C/T Intron 2 Affy 6.0 24.1 0.548 1.0 (0.9–1.1) 0.966 1.1 (0.9–1.2) 0.308 0.9 (0.8–1.1) 0.283
rs2113200 T/A Intron 2 Affy 6.0 24.5 0.864 1.0 (0.9–1.1) 0.723 1.0 (0.9–1.2) 0.554 0.9 (0.8–1.1) 0.203
rs9929498 G/A Intron 2 Targeted 26.4 0.729 1.0 (0.9–1.1) 0.841 1.0 (0.8–1.1) 0.686 1.0 (0.8–1.3) 0.918
rs2059254 C/T Intron 2 Both 16.6 0.469 1.0 (0.9–1.2) 0.690 1.2 (1.0–1.4) 0.029 0.8 (0.7–1.0) 0.049
rs9925923 C/T Intron 2 Affy 6.0 17.1 0.578 1.0 (0.9–1.2) 0.678 1.2 (1.0–1.4) 0.024 0.8 (0.7–1.0) 0.049
rs12919719 C/G Intron 2 Both 17.6 0.792 1.0 (0.9–1.1) 0.913 1.2 (1.0–1.4) 0.057 0.8 (0.7–1.0) 0.044
rs4076177 A/G Intron 2 Targeted 20.8 0.668 1.1 (0.9–1.2) 0.508 1.1 (0.9–1.3) 0.307 1.0 (0.8–1.3) 0.904
rs12599393 C/T Intron 2 Affy 6.0 17.1 0.638 1.0 (0.9–1.1) 0.752 1.1 (1.0–1.3) 0.129 0.8 (0.7–1.0) 0.020
rs1862748 C/T Intron 2 Both 18.1 0.707 1.0 (0.9–1.1) 0.834 1.1 (1.0–1.3) 0.100 0.8 (0.7–1.0) 0.027
rs10431923 T/G Intron 2 Affy 6.0 45.2 0.311 1.0 (1.0–1.2) 0.424 1.1 (1.0–1.2) 0.222 1.0 (0.9–1.1) 0.875
rs10431924 C/T Intron 2 Targeted 44.7 0.735 1.0 (0.9–1.2) 0.631 1.1 (0.9–1.2) 0.355 1.0 (0.8–1.2) 0.703
rs4783573 G/A Intron 2 Both 21.9 0.370 1.0 (0.9–1.1) 0.545 1.0 (0.9–1.2) 0.598 1.0 (0.9–1.2) 0.707
rs7188750 G/A Intron 5 Both 18.5 0.226 1.0 (0.9–1.2) 0.573 0.9 (0.8–1.1) 0.354 1.2 (1.0–1.4) 0.052
rs8059139 A/G Intron 6 Both 11.1 0.326 1.0 (0.9–1.2) 0.758 1.0 (0.8–1.2) 0.627 1.1 (0.9–1.4) 0.339
rs3785076 A/G Intron 10 Targeted 11.7 0.327 1.0 (0.8–1.2) 0.895 1.1 (0.8–1.3) 0.684 0.9 (0.7–1.3) 0.636
rs4783689 C/T Intron 11 Both 32.9 0.250 1.0 (1.0–1.1) 0.372 1.1 (1.0–1.2) 0.134 1.0 (0.8–1.1) 0.668
rs16958383 G/A Intron 12 Targeted 20.7 0.542 1.0 (0.8–1.1) 0.514 0.8 (0.7–1.0) 0.020 1.3 (1.0–1.7) 0.062
rs10500545 A/T Intron 13 Targeted 12.6 0.989 1.0 (0.8–1.2) 0.692 0.9 (0.7–1.1) 0.194 1.1 (0.8–1.5) 0.415
rs9935563 C/T Intron 13 Targeted 35.7 0.620 1.0 (0.9–1.1) 0.690 1.1 (0.9–1.3) 0.213 0.8 (0.6–1.0) 0.041
rs9925080 G/A Intron 13 Affy 6.0 9.3 0.182 1.0 (0.9–1.1) 0.724 0.9 (0.7–1.1) 0.281 1.1 (0.9–1.4) 0.519
rs9925161 G/A Intron 13 Both 9.3 0.111 1.0 (0.9–1.1) 0.879 0.9 (0.7–1.1) 0.304 1.1 (0.9–1.4) 0.377
rs8061932 T/C Intron 14 Both 22.8 0.855 1.0 (0.9–1.1) 0.623 0.9 (0.8–1.0) 0.073 1.1 (1.0–1.3) 0.176
rs3785078 A/C Intron 14 Targeted 13.7 0.585 0.9 (0.8–1.1) 0.465 0.9 (0.7–1.1) 0.223 1.1 (0.8–1.5) 0.634
rs9927789 A/C Intron 14 Targeted 19.0 0.214 1.0 (0.9–1.2) 0.888 0.9 (0.8–1.1) 0.565 1.1 (0.9–1.5) 0.396
rs7203904 G/C Intron 14 Targeted 32.5 0.706 1.0 (0.9–1.1) 0.896 0.9 (0.8–1.0) 0.128 1.2 (1.0–1.5) 0.098
rs2276329 T/C Intron 14 Both 9.7 0.257 1.0 (0.9–1.2) 0.952 0.9 (0.8–1.1) 0.582 1.1 (0.9–1.3) 0.511
rs13689 T/C 3′ UTR Affy 6.0 19.0 0.397 1.0 (0.9–1.1) 0.760 0.9 (0.8–1.1) 0.220 1.2 (1.0–1.4) 0.062
rs17690554 C/G 3′ FRh Affy 6.0 19.1 0.399 1.0 (0.9–1.2) 0.834 0.9 (0.8–1.1) 0.214 1.2 (1.0–1.4) 0.082
rs12447341 C/T 3′ FRh Targeted 29.0 0.698 1.0 (0.9–1.1) 0.507 1.1 (0.9–1.3) 0.474 0.8 (0.6–1.0) 0.057
a

Major/minor alleles as determined by allele frequency among genotyped controls

b

Genotyping and study phase: Affymetrix targeted genotyping among 1,062 cases and 1,069 controls from phase 1 (Targeted), or Affymetrix 6.0 genotyping among 1,104 cases and 1,109 controls from Phase 1 and 969 cases and 975 controls from phase 2 (Affy 6.0), or genotyped by both (Both)

c

Minor allele freqency among genotyped controls

d

Hardy–Weinberg equilibrium test among controls

e

Risk of breast cancer per minor allele, adjusted for age, education, and study phase (when appropriate); A major allele, B minor allele; P value for trend

f

Premenopausal Women: 717 cases and 692 controls from phase 1 (Targeted), or 745 caes and 758 controls from phase 1 and 528 cases and 516 controls from phase 2 (Affy 6.0)

g

Postmenopausal Women: 345 cases and 377 controls from phase 1 (Targeted), or 369 caes and 419 controls from phase 1 and 441 cases and 459 controls from phase 2 (Affy 6.0)

h

3′ FR: 3′ flanking region, downstream of the CDH1 gene

Bold values considered to be significant P ≤ 0.05